• The experience of the use of «Ergoferon» in children with ARVI
To content

The experience of the use of «Ergoferon» in children with ARVI

SOVREMENNAYA PEDIATRIYA. 2015.1(65):30-33; doi 10.15574/SP.2015.65.30


The experience of the use of «Ergoferon» in children with ARVI


Kramarev S. A., Zakordonets L. V.

A.A. Bogomolets National Medical University, Kyiv, Ukraine


Objective. To study the effectiveness of the «Ergoferon» preparation in the treatment of children with acute respiratory viral infections (ARVI).


Patients and methods. A total of 60 children with ARVI of moderate severity in the age from 4 to 17 years were under observation. Children of the main group (30 persons) had received «Ergoferon» in the complex therapy. Children in the control group (30 persons) had received only symptomatic treatment of ARVI. On the first and third day of treatment, saliva samples were collected for determination of the levels of secretory immunoglobulin A, alpha-interferon, and gamma-interferon.


Results. Due to the application of «Ergoferon» the duration of the main manifestations of ARVI (nasal congestion, rhinitis, catarrhal symptoms, fever and weakness) were reduced into one-two days. The Immunomodulatory effect of the preparation, increased secretion of secretory immunoglobulin A, alpha- and gamma-interferons during the reduced baseline products is established.


Conclusions. The use of «Ergoferon» during the ARVI in children is a safe and perspective method of treatment of present disease.


Key words: acute respiratory viral infections, children, treatment, Ergoferon.


1. Захарова ИН, Малиновская ВВ, Коровина НА и др. 2011. Клинико-иммунологическое обоснование местного применения интерферонов при респираторной вирусной инфекции у детей. Вопр совр педиатрии. 10: 117—122.

2. Компендиум (лекарственные препараты). Под ред. В Коваленко. К, Морион ЛТД. 2013: 2360.

3. Bright RA, Shay DK, Shu B et al. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 295: 891-894.

4. Rhedin S, Lindstrand A, Rotzen-Оstlund M et al. 2014. Clinical utility of PCR for common viruses in acute respiratory illness. Pediatrics. 133(3): 538—545.

5. Henderson D. 2014, Aug 4. Influenza: Complications in 1 in 3 рreviously healthy kids. Medscape Medical News. http://www.medscape.com/index/list_1102_2.

6. http://www.dsesu.gov.ua/ua/sanepidsituatsiya/hrvi-a-hryp/item/693-zakhvoriuvanist-naselennia-na-hryp-ta-hostri-respiratorni-virusni-infektsii-u-2013-2014-rokakh-v-ukraini.

7. Bright RA, Medina MJ, Xu X et al. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 366: 1175—1181.